Jazz Pharmaceuticals Beats Q4 Estimates with $1.2B Revenue, Guides $4.25–$4.5B for 2026
Jazz Pharmaceuticals reported Q4 revenue of $1.2 billion, surpassing estimates by $30 million and marking 10% year-over-year growth and its highest quarter to date. Management projected 2026 revenue of $4.25–$4.5 billion and highlighted upcoming zanidatamab launch, Modeyso and Zepzelca rollouts, plus Epidiolex and Xywav momentum.
1. Q4 Performance
Jazz Pharmaceuticals generated $1.2 billion in Q4 revenue, topping consensus by $30 million and delivering 10% year-over-year growth. This marks the company’s highest quarterly revenue and extends its streak to 21 consecutive years of top-line expansion.
2. Portfolio and Pipeline Momentum
Management emphasized momentum from its rare disease and oncology portfolio, including the planned launch of zanidatamab in gastroesophageal adenocarcinoma and ongoing commercialization of Modeyso and Zepzelca. The company also cited continued strength from Epidiolex in epilepsy and Xywav in narcolepsy.
3. FY2026 Guidance and Outlook
Jazz projects full-year 2026 revenue between $4.25 billion and $4.5 billion, reflecting pipeline contributions and market growth. Consensus expectations sit near the top of this range, underscoring the importance of successful product launches and commercial execution.
4. Analyst Rating Update
TD Cowen raised its price target on Jazz Pharmaceuticals to $220 from $205 and maintained a Buy rating, citing improved modeling and enhanced visibility on the clinical pipeline heading into 2026.